Celcuity Inc. (NASDAQ:CELC)

There are currently no videos for this stock.
To request coverage of this stock, please click the green request video box on the right.
Bands Volume 200 SMA 50 SMA 20 SMA Videos Alerts Articles Events
CELC Weekly Chart

Old Forum Content for CELC

Make a Forum Post
Become a member to view recent forum posts. Already a member? Sign in here.
Loading...
  • woodman: $CELC continues to work decently. Long from lower.
  • woodman: $CELC contineus to work. Long, but data are coming on 12/11/25. https://pryzm.ozmosi.com/product/982
  • woodman: @pperlroth $INSM - for sure. You may also like these well performing bios: $CELC $ZBIO $BBIO. Long all of those. Also long $AQST $GPCR and $VKTX, but they are a little stuck right now, and $AXSM. Watching $NKTR (consolidating in a high base) with a placeholder.
  • pperlroth: @woodman $INSM $CELC $ZBIO $BBIO $AQST $GPCR $VKTX $AXSM $NKTR I bought some AQST with the potential approval upcoming. I will look at the others. Been in and out of $BBIO. Got one for. you $ACHV. Fast track for approval potentially for smoking cessation treatment.
  • joelsg1: @woodman $INSM $CELC $ZBIO $BBIO $AQST $GPCR $VKTX $AXSM $NKTR Still holding posted Dec. $125-145 call spreads now filled with 2 weeks to go on $AXSM.
  • bob212: @pperlroth $INSM $CELC $ZBIO $BBIO $AQST $GPCR $VKTX $AXSM $NKTR $ACHV
  • woodman: $XBI $IBB - current bio holdings: $ZBIO $CELC $BBIO $INSM $NKTR (and a small bit of $VKTX and $GPCR). Kicking myself for not buying $VRDN and $AXSM which were on my same shopping list (along with these others) months ago.
  • Motorman: @woodman $XBI $IBB $ZBIO $CELC $BBIO $INSM $NKTR $VKTX $GPCR $VRDN $AXSM IBD wrote a piece on $CELC Nov 10. Did not take a piece, now up 25% in 2 weeks. Missed it. More left in tank?
  • joelsg1: @woodman $XBI $IBB $ZBIO $CELC $BBIO $INSM $NKTR $VKTX $GPCR $VRDN $AXSM Awaiting clinical trial results for $AXSM Alzheimers and depression drugs due this Q-L.
  • woodman: @joelsg1 $XBI $IBB $ZBIO $CELC $BBIO $INSM $NKTR $VKTX $GPCR $VRDN $AXSM - I'm not fond of biotech binary events. Too many scars. Alzheimer's is a tough area, but I'll read up on it.
  • woodman: @Motorman $XBI $IBB $ZBIO $CELC $BBIO $INSM $NKTR $VKTX $GPCR $VRDN $AXSM - I don't think I saw the IBD article, but I bought CELC back right around then. I had it in the $50s, but didn't hang on, unfortunately. Bought it back in the mid $70s.
  • woodman: $Biotech holding up well. I have several, and only $NKTR is giving me a caution sign. Others (in no particular order) are doing fine: $CELC $INSM $BBIO $ZBIO $GPCR $VKTX
  • woodman: Current Biotech positions: $VKTX $GPCR $INSM $NKTR $BBIO $ZBIO $CELC $LABU. I've been building these up over the last couple months, but not reporting on them because biotech is a minefield and I was reluctant to mention them frequently. But the path has been undeniable for so many bios. I'm not smoking hopium on these, though. I'm in for the charts with a dash of good stories that could keep them going. It is vital, however, to know their catalyst dates or you could get T-boned without seeing it coming. In fact, I am probably in unsafe harbor having this many at once; I need to re-review each of them for the reason stated.
  • kenb: @woodman $VKTX $GPCR $INSM $NKTR $BBIO $ZBIO $CELC $LABU and adding $ARDX to the list. I'm still holding a large chunk and it's moving up as well from the depths finally.
  • woodman: @kenb $VKTX $GPCR $INSM $NKTR $BBIO $ZBIO $CELC $LABU $ARDX - I like ARDX as a biotech with a commercialized product serving two indications (IBS with constipation and hyperphosphatemia). My short-intermediate concern is over its appeal on the Xphoza ...
  • joelsg1: @woodman $VKTX $GPCR $INSM $NKTR $BBIO $ZBIO $CELC $LABU Tailwind for group is rapid changes at FDA, particulary the Center for Drug Development and Research, to emphasize faster and less rigorous drug approvals.
  • woodman: @joelsg1 $VKTX $GPCR $INSM $NKTR $BBIO $ZBIO $CELC $LABU - Yep, but who the hell knows what's really going on over at FDA and CEDR (Center for Drug Evaluation and Research) now. Cluster F with all the changes in personnel, string-pulling, and whatever guiding priniples there now. Here's some info on the brand new head of CEDR - https://www.fiercepharma.com/pharma/fda-names-longtime-oncology-chief-richard-pazdur-its-new-cder-director
  • joelsg1: @woodman $VKTX $GPCR $INSM $NKTR $BBIO $ZBIO $CELC $LABU Seems it's pay-to-play over there, in keeping with Administration priorities.
  • woodman: @joelsg1 $VKTX $GPCR $INSM $NKTR $BBIO $ZBIO $CELC $LABU - And science has taken a back seat.
  • woodman: $CELC - Damn, I had this in Sept, but didn't hold on.
  • woodman: $INSM $CELC - two other biotechs I'm long. Admittedly, I need to research catalysts/binary events, because I'm interested only in riding the biotechs higher, but not gambling on binary events. $INSM has Baker Brothers backing, which is always nice. $CELC I believe will have data by end of the year. I need to pinpoint that better.
  • woodman: $CELC doing well
  • woodman: $CELC - my goodness. Np. https://www.stocktitan.net/news/CELC/celcuity-announces-clinically-meaningful-improvement-in-both-sa2az9rsygrr.html
Visit the Trading Forum to join in the discussion.
Stock Price $112.99
Change 0.43%
Volume 576,414

Celcuity Inc is active in the healthcare domain. It is a cellular analysis company that is discovering new cancer sub-types and commercialising diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The company's proprietary CELx diagnostic platform uses the patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it.

Request Video of CELC
Already a member? Sign in here.
Past Month

Leading Peers

Past Month

Lagging Peers

Dan Fitzpatrick

Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:

  • Nightly video Strategy Sessions with a game plan for tomorrow
  • Got a stock you want Dan to look at? Just ask.
  • Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
  • Access to over 90,400 stock analysis videos
  • Access an ever expanding library (90,400) of educational videos that will save you time and make you money

Join a team of friends and traders that have one thing in common; a burning desire to succeed.

Become a Member Today!

Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...

Satisfaction Guaranteed!

Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!